"","Rank","NCT.ID","Title","Recruitment","Study.Results","Conditions","Interventions","Sponsors","Gender","Age.Groups","Phases","Enrollment","Funded.Bys","Study.Types","Study.Designs","Other.IDs","First.Received","Start.Date","Completion.Date","Last.Updated","Last.Verified","Acronym","Primary.Completion.Date","Outcome.Measures","URL","study.location"
"80537",80537,"NCT00357396","Busulfan, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk Ewing's Tumors","Completed","No Results Available","Sarcoma","Biological: graft versus host disease prophylaxis/therapy|Drug: busulfan|Drug: melphalan|Drug: thiotepa|Procedure: allogeneic bone marrow transplantation|Procedure: allogeneic hematopoietic stem cell transplantation|Procedure: peripheral blood stem cell transplantation","Memorial Sloan-Kettering Cancer Center","Both","Child|Adult","Phase II",30,"Other","Interventional","Primary Purpose: Treatment","CDR0000487592|MSKCC-05059","July 26, 2006","01/06/2005",NA,"November 10, 2009","01/11/2009","",2009-10-01,"Disease-free survival at 1 year|Overall survival|Morbidity and mortality|Incidence of acute and chronic graft-vs-host disease (GVHD)|Biologic response of minimal residual disease","http://ClinicalTrials.gov/show/NCT00357396","United States"
"80661",80661,"NCT00528996","An Efficacy and Safety Study to Compare Three Doses of BEA 2180 BR to Tiotropium and Placebo in the Respimat Inhaler.","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: BEA 2180 BR|Drug: tiotropium","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",2080,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Primary Purpose: Treatment","1205.14|2007-007946-42","September 12, 2007","01/09/2007",NA,"July 16, 2010","01/07/2010","",2009-05-01,"The primary endpoint in this study is trough FEV1 response after 24 weeks.|Trough FEV1 response after 1, 2, 4, 8, 12, and 18 weeks","http://ClinicalTrials.gov/show/NCT00528996","United States, &nbsp; Canada, &nbsp; Germany, &nbsp; Hungary, &nbsp; Korea, Republic of, &nbsp; Mexico, &nbsp; Poland, &nbsp; Russian Federation, &nbsp; Spain, &nbsp; Taiwan"
"80672",80672,"NCT00571896","The Use of SennaS for Prevention of Post-Operative Constipation After Urogynecologic Surgery","Completed","No Results Available","Constipation","Drug: Senna+ docusate|Drug: placebo","Hartford Hospital","Female","Adult|Senior","Phase II|Phase III",72,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","PATE002472HE","December 10, 2007","01/01/2008",2009-06-01,"July 1, 2009","01/07/2009","",2009-06-01,"1. Time to first bowel movement after surgery. 2. Need for magnesium citrate or enemas in the immediate post-operative period.|Straining and pain with bowel movements in the immediate post-operative period","http://ClinicalTrials.gov/show/NCT00571896","United States"
"80721",80721,"NCT00647296","Safety and Tolerability Study of KNS-760704 in Amyotrophic Lateral Sclerosis (ALS)","Completed","No Results Available","Amyotrophic Lateral Sclerosis","Drug: KNS-760704","Knopp Neurosciences","Both","Adult|Senior","Phase II",102,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","KNS-760704-CL201","March 26, 2008","01/03/2008",2009-10-01,"November 6, 2009","01/11/2009","CL201",2009-09-01,"To evaluate the safety and tolerability of oral administration of 3 dosage levels of KNS-760704 compared to placebo for 12 weeks in patients with ALS (Part 1)|To evaluate the long-term safety and tolerability of oral administration of 2 dosage levels of KNS 760704 in ALS patients (Part 2)|To evaluate the effects of KNS-760704 on measures of clinical function|To evaluate the reliability and clinical predictive value of upright and supine vital capacity|To evaluate the effects of KNS-760704 on selected protein levels in blood and cerebrospinal fluid","http://ClinicalTrials.gov/show/NCT00647296","United States"
"80790",80790,"NCT00739596","Blood Pressure Lowering of Aliskiren HCTZ Versus Amlodipine in Stage 2 Hypertension in African Americans","Completed","Has Results","Hypertension","Drug: Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks|Drug: Amlodipine: 8 weeks","Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",332,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","CSPP100AUS03","August 21, 2008","01/07/2008",2009-03-01,"December 14, 2010","01/12/2010","ATLAAST",2009-03-01,"Change in Mean Sitting Systolic Blood Pressure (MSSBP) After 8 Weeks of Treatment|Change in Mean Sitting Diastolic Blood Pressure (MSDBP) After 8 Weeks of Treatment|Change in Mean Sitting Pulse Pressure (MSPP) After 8 Weeks of Treatment|Proportion of Responders After 8 Weeks of Treatment.|Proportion of Patients Achieving BP Control After 8 Weeks of Treatment","http://ClinicalTrials.gov/show/NCT00739596","United States"
"81025",81025,"NCT01180296","Oral Progesterone for Prevention of Preterm Birth","Completed","No Results Available","Preterm Birth","Drug: oral micronized progesterone|Drug: Identical Placebo tablet","Fetal Medicine Foundation","Female","Adult","Phase III",33,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","MVH-MP-Pilot-RCT","August 10, 2010","01/11/2006",2009-01-01,"August 11, 2010","01/08/2010","",2009-01-01,"Rate of recurrent preterm birth|Serum Progesterone Levels","http://ClinicalTrials.gov/show/NCT01180296","United States"
"81168",81168,"NCT00058097","Tipifarnib and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme","Completed","No Results Available","Brain and Central Nervous System Tumors","Drug: tipifarnib|Radiation: radiation therapy","National Cancer Institute (NCI)","Both","Adult|Senior","Phase II",NA,"NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000285732|NABTT-2200|JHOC-NABTT-2200","April 7, 2003","01/08/2003",NA,"April 24, 2009","01/04/2004","",2009-01-01,"","http://ClinicalTrials.gov/show/NCT00058097","United States"
"81186",81186,"NCT00091897","Rituximab to Treat Stiff Person Syndrome","Completed","No Results Available","Stiff Person Syndrome","Drug: Rituximab","National Institute of Neurological Disorders and Stroke (NINDS)","Both","Adult|Senior","Phase II",24,"NIH","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator)|Primary Purpose: Treatment","040287|04-N-0287","September 18, 2004","01/09/2004",NA,"January 28, 2010","01/05/2009","",2009-05-01,"To evaluate the efficacy, safety of the chimeric monoclonal antibody Rituximab to deplete B lymphocytes in patients with Stiff Person Syndrome with high anti-GAD antibodies.|The Heightened Sensitivity Scale will be used as a secondary outcome measure.","http://ClinicalTrials.gov/show/NCT00091897","United States"
"81238",81238,"NCT00171197","A 1-year Extension Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Effects on Liver Iron Concentration of Deferasirox and Deferoxamine in Children and Adults With Sickle Cell Disease and Transfusional Hemosiderosis","Completed","No Results Available","Sickle Cell Disease","Drug: Deferasirox","Novartis Pharmaceuticals","Both","Child|Adult|Senior","Phase II",170,"Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","CICL670A109E1","September 12, 2005","01/05/2004",NA,"December 9, 2010","01/12/2010","",2009-07-01,"Evaluate the long-term safety and tolerability profile of ICL670|Allow patients to continue iron chelation therapy|Estimate the absolute and relative change of liver iron content (LIC) and total body iron excretion (TBIE)|Evaluate the relationship between hepatic iron and potential surrogate markers","http://ClinicalTrials.gov/show/NCT00171197","United States, &nbsp; Canada, &nbsp; France, &nbsp; Italy, &nbsp; United Kingdom"
"81459",81459,"NCT00472797","Rebif New Formulation (RNF) Quality of Life (QOL) Study","Completed","Has Results","Relapsing Multiple Sclerosis","Drug: Rebif New Formulation Non Titrated|Drug: Rebif New Formulation Titrated","EMD Serono","Both","Adult","Phase III",232,"Industry","Interventional","Allocation: Randomized|Control: Uncontrolled|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Supportive Care","27955","May 10, 2007","01/04/2007",2009-11-01,"August 17, 2010","01/08/2010","RebiQoL",2009-02-01,"Percent Change in Global Side Effects (GSE) on Multiple Sclerosis Treatment Concerns Quesionnaire (MSTCQ)|Total Score for Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Change in Score From Baseline to Week 12 for All Domains Other Than Global Side Effects on Multiple Sclerosis Treatment Concerns Questionnaire (MSTCQ)|Total Score on Short-Form McGill Pain Questionnaire (SF-MPQ): Change in Baseline to Wk 12|Tolerability in Pain Using Visual Analog Scale (VAS)|Tolerability - Redness at Injection Site","http://ClinicalTrials.gov/show/NCT00472797","United States"
"81500",81500,"NCT00574197","Enteric-coated Mycophenolate Sodium (Myfortic?ó) in Heart Transplant Recipients","Completed","No Results Available","Gastrointestinal Symptoms|Heart Transplantation","Drug: Mycophenolate Sodium","Cedars-Sinai Medical Center|Novartis Pharmaceuticals","Both","Adult|Senior","Phase IV",11,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","9810","December 13, 2007","01/06/2006",2009-12-01,"July 21, 2010","01/08/2009","",2009-12-01,"Side-effects using the GSRS (Gastrointestinal Symptoms Rating Scale), GI complications and GI adverse events|Incidence of biopsy proven acute rejection, graft loss, and death","http://ClinicalTrials.gov/show/NCT00574197","United States"
"81525",81525,"NCT00617097","Paracervical Block in First Trimester Surgical Abortions","Completed","No Results Available","Pain|Abortion, Induced","Drug: lidocaine|Drug: ketorolac and lidocaine","Johns Hopkins University|Oregon Health and Science University","Female","Adult","Phase II|Phase III",50,"Other","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","NA_00013075|SFP1-1","December 28, 2007","01/01/2008",2009-06-01,"June 8, 2009","01/06/2009","",2009-05-01,"The mean difference in distance (in millimeters) on a 100-mm Visual Analogue Scale (VAS) taken during specific time intervals throughout termination procedure.","http://ClinicalTrials.gov/show/NCT00617097","United States"
"81613",81613,"NCT00760097","Adjunctive Transcranial Direct Current Stimulation for Cognition in Major Depression","Completed","No Results Available","Depression","Device: Transcranial direct stimulation","University of California, Los Angeles","Both","Adult|Senior","Phase IV",18,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Single Blind (Subject)|Primary Purpose: Diagnostic","aTDCS in MDD","September 24, 2008","01/09/2007",2009-05-01,"August 6, 2009","01/08/2009","aTDCS",2009-05-01,"To test our hypotheses, assessments of cognition, mood, and brain activity will be performed on three occasions|ADVERSE EVENT REPORTS Subjects will be asked about adverse events at the end of each treatment session","http://ClinicalTrials.gov/show/NCT00760097","United States"
"81633",81633,"NCT00797797","Study of Milnacipran Added to Pregabalin for Treatment of Fibromyalgia","Completed","No Results Available","Fibromyalgia","Drug: pregabalin|Drug: milnacipran","Forest Laboratories","Both","Adult|Senior","Phase III",364,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","MLN-MD-15","November 24, 2008","01/11/2008",2010-01-01,"April 29, 2010","01/04/2010","",2009-11-01,"PGIC responder rate at end of study|Change from baseline in VAS 1-week pain recall at end of study","http://ClinicalTrials.gov/show/NCT00797797","United States"
"82027",82027,"NCT00085098","Radiation Therapy Compared With Chemotherapy and Radiation Therapy in Treating Patients With Newly Diagnosed Primary CNS Germ Cell Tumor","Completed","No Results Available","Brain and Central Nervous System Tumors","Biological: filgrastim|Drug: carboplatin|Drug: cisplatin|Drug: cyclophosphamide|Drug: etoposide|Radiation: radiation therapy","Children's Oncology Group|National Cancer Institute (NCI)","Both","Child|Adult","Phase III",225,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Masking: Open Label|Primary Purpose: Treatment","CDR0000367294|COG-ACNS0232","June 10, 2004","01/01/2007",NA,"November 20, 2010","01/11/2010","",2009-08-01,"Event-free survival|Response|Toxicity|Quality of life","http://ClinicalTrials.gov/show/NCT00085098","United States, &nbsp; Australia, &nbsp; Canada, &nbsp; Puerto Rico"
"82157",82157,"NCT00307398","Anecortave Acetate Risk-Reduction Trial (AART)","Completed","No Results Available","Dry AMD","Drug: Anecortave Acetate","Alcon Research","Both","Adult|Senior","Phase III",2500,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double-Blind|Primary Purpose: Treatment","C-02-60","March 24, 2006","01/03/2004",NA,"May 7, 2009","01/05/2009","",2009-01-01,"To demonstrate that anecortave acetate is safe and effective in arresting the progression of dry AMD to wet AMD in at-risk patients|Time to development of sight threatening CNV","http://ClinicalTrials.gov/show/NCT00307398","United States"
"82158",82158,"NCT00118898","Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive Adults","Completed","Has Results","HIV Infections","Drug: Abacavir/Lamivudine|Drug: Atazanavir|Drug: Efavirenz|Drug: Emtricitabine/Tenofovir disoproxil fumarate|Drug: Ritonavir|Drug: Abacavir/Lamivudine placebo|Drug: Emtricitabine/Tenofovir disoproxil fumarate placebo","AIDS Clinical Trials Group|National Institute of Allergy and Infectious Diseases (NIAID)","Both","Child|Adult|Senior","Phase III",1864,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","ACTG A5202|1U01AI068636|ACTG 5224s","July 7, 2005","01/09/2005",2009-11-01,"January 10, 2011","01/01/2011","",2009-11-01,"Time From Randomization to Virologic Failure|Time From Treatment Dispensation to a Grade 3/4 Safety Event|Time From Treatment Dispensation to Treatment Modification|Time From Treatment Dispensation to Regimen Failure (First Occurrence of Virologic Failure or Treatment Modification)|The Number of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL|Number of Participants With HIV-1 RNA Levels Less Than 200 Copies/mL|Change in CD4 Count (Cells/mm3) From Baseline|Number of Participants With Virologic Failure and Emergence of Major Resistance|Number of Participants Experiencing Certain Targeted Clinical Events, Including Death, AIDS-defining Illness, and HIV-1 Related Events.|Change in Fasting Total Cholesterol Level From Baseline|Change in Fasting High-density Lipoprotein (HDL) Cholesterol Level From Baseline|Change in Fasting Non-high Density Lipoprotein (Non-HDL) Cholesterol Level From Baseline|Change in Fasting Triglyceride Level From Baseline","http://ClinicalTrials.gov/show/NCT00118898","United States, &nbsp; Puerto Rico"
"82202",82202,"NCT00378898","Feasibility of Placing Bravo PH Capsule in Proximal Esophagus","Completed","No Results Available","Gastroesophageal Reflux Disease","Device: Bravo PH capsule|Procedure: Fluoroscopy","Vanderbilt University","Both","Adult|Senior","Phase III",25,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Diagnostic","60724","September 20, 2006","01/09/2006",2009-07-01,"January 11, 2010","01/01/2010","bravo",2009-03-01,"Patient tolerance to a Bravo PH monitor in the proximal esophagus after 48 hours|Collection of and comparison of data between distal and proximal Bravo capsule","http://ClinicalTrials.gov/show/NCT00378898","United States"
"82278",82278,"NCT00484198","Randomized, Double-Blind Active Comparator-Controlled Study of Rivoglitazone in Type 2 Diabetes Mellitus","Completed","No Results Available","Type 2 Diabetes Mellitus","Drug: pioglitazone|Drug: placebo|Drug: rivoglitazone HCl|Drug: rivoglitazone HCl","Daiichi Sankyo Inc.","Both","Adult|Senior","Phase III",1820,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CS0011-A-U301","June 7, 2007","01/04/2007",2009-02-01,"February 1, 2010","01/02/2010","",2009-02-01,"Glycemic control - HbA1c|Glycemic control - FPG Responder rates - A1C Effects on lipid parameters","http://ClinicalTrials.gov/show/NCT00484198","United States, &nbsp; Argentina, &nbsp; Austria, &nbsp; Chile, &nbsp; Czech Republic, &nbsp; Germany, &nbsp; Hungary, &nbsp; India, &nbsp; Latvia, &nbsp; Mexico, &nbsp; Peru, &nbsp; Puerto Rico, &nbsp; Romania, &nbsp; Serbia, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Ukraine, &nbsp; United Kingdom"
"82318",82318,"NCT00556998","A Multiple-Dose Study To Evaluate The Pharmacokinetics And Safety Of Voriconazole In Immunocompromised Adolescents","Completed","No Results Available","Pharmacokinetics","Drug: Voriconazole","Pfizer","Both","Child","Phase I|Phase II",26,"Industry","Interventional","Allocation: Non-Randomized|Endpoint Classification: Pharmacokinetics Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","A1501081","November 9, 2007","01/06/2008",2009-12-01,"August 2, 2010","01/08/2010","",2009-12-01,"Pharmacokinetic parameters of voriconazole in adolescents compared to historical adult data.|Safety and tolerability of voriconazole in adolescents","http://ClinicalTrials.gov/show/NCT00556998","United States"
"82335",82335,"NCT00586898","Rapid Hormonal Cycling as Treatment for Patients With Prostate Cancer: The Men's Cycle","Completed","No Results Available","Prostate|Cancer|Hormonal Cycling","Drug: GnRH|Drug: Ketoconazole|Drug: Bicalutamide|Drug: Testosterone transdermal gel|Drug: Estrogen transdermal patch","Memorial Sloan-Kettering Cancer Center","Male","Adult|Senior","Phase II",36,"Other","Interventional","Control: Uncontrolled|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","01-085","December 21, 2007","01/07/2001",2009-03-01,"July 9, 2009","01/07/2009","",2009-03-01,"To determine the response to rapid hormonal cycling in patients with non-castrate prostate cancer.","http://ClinicalTrials.gov/show/NCT00586898","United States"
"82391",82391,"NCT00686998","Phase IIA Study in Patients With Schizophrenia","Completed","No Results Available","Schizophrenia","Drug: AZD2624|Drug: Olanzapine|Drug: Placebo","AstraZeneca","Both","Adult","Phase II",110,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","D0970C00004","May 28, 2008","01/05/2008",2009-05-01,"August 18, 2009","01/08/2009","",2009-05-01,"Change in PANSS total score|Safety and Tolerability of AZD2624 vs Placebo|Pharmacokinetic evaluation","http://ClinicalTrials.gov/show/NCT00686998","United States"
"82392",82392,"NCT00685698","Safety and Efficacy Study of TG-873870 (Nemonoxacin) in Diabetic Foot Infections","Completed","No Results Available","Diabetic Foot Infections","Drug: TG-873870 (Nemonoxacin)","TaiGen Biotechnology Co., Ltd.","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Treatment","TG-873870-04","May 22, 2008","01/06/2008",2009-06-01,"January 18, 2010","01/01/2010","",2009-04-01,"Clinical Success|Safety Evaluation|Microbiological Success Rate|PK and PD Evaluation","http://ClinicalTrials.gov/show/NCT00685698","United States, &nbsp; South Africa, &nbsp; Taiwan, &nbsp; Thailand"
"82407",82407,"NCT00709098","Safety Study Extension of Iloprost Power 15 in Pulmonary Arterial Hypertension","Completed","No Results Available","Pulmonary Arterial Hypertension","Drug: iloprost|Drug: iloprost","Actelion","Both","Adult|Senior","Phase III",49,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Safety Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","AC-063A302","July 1, 2008","01/06/2008",2009-12-01,"April 30, 2010","01/04/2010","PROWESS 15 Ext",2009-11-01,"Treatment-emergent adverse events|Treatment-emergent serious adverse events|Adverse events leading to premature discontinuation of study drug|Treatment-emergent adverse events and serious adverse events leading to study drug discontinuation","http://ClinicalTrials.gov/show/NCT00709098","United States, &nbsp; Austria, &nbsp; Germany"
"82426",82426,"NCT00748098","Polysomnography Study of GSK1838262 (XP13512) Extended Release Tablets Versus Placebo in Restless Legs Syndrome (RLS) and Associated Sleep Disturbance","Completed","No Results Available","Restless Legs Syndrome (RLS)","Drug: GSK1838262 Extended Release Tablets|Drug: Placebo","GlaxoSmithKline","Both","Adult|Senior","Phase III",136,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","RXP110908","September 5, 2008","01/10/2008",2009-07-01,"August 12, 2010","01/08/2010","",2009-07-01,"Change from baseline to end of each treatment period in Wake Time During Sleep (WTDS) measured by polysomnography|Change from baseline to end of each treatment period in Periodic Limb Movements associated with Arousal per hour (PLMAI) measured by polysomnography|Assess safety, tolerability, polysomnography efficacy measures, and patient reported outcomes.","http://ClinicalTrials.gov/show/NCT00748098","United States"
"82441",82441,"NCT00758498","Study of the Effect of Armodafinil Treatment in Healthy Subjects With Excessive Sleepiness Associated With Jet Lag Disorder","Completed","Has Results","Excessive Sleepiness","Drug: armodafinil|Drug: armodafinil|Drug: placebo","Cephalon","Both","Adult","Phase III",427,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","C10953/3065/ES/MN","September 23, 2008","01/09/2008",2009-02-01,"June 11, 2010","01/06/2010","",2009-02-01,"Multiple Sleep Latency Test (MSLT)|Patient Global Impression of Severity (PGI-S)|Karolinska Sleepiness Scale (KSS)|Multiple Sleep Latency Test (MSLT)|Patient Global Impression of Severity (PGI-S)","http://ClinicalTrials.gov/show/NCT00758498","United States"
"82487",82487,"NCT00813098","Study of LX1031 in Subjects With Non-Constipating Irritable Bowel Syndrome","Completed","Has Results","Irritable Bowel Syndrome","Drug: LX1031 High Dose|Drug: LX1031 Low Dose|Drug: Placebo","Lexicon Pharmaceuticals","Both","Adult|Senior","Phase II",155,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","Protocol LX1031.1-201-IBS|LX1031.201","December 19, 2008","01/12/2008",2010-08-01,"November 4, 2010","01/11/2010","",2009-07-01,"Subjects Who Experienced Relief of IBS Pain and Discomfort at Week 4|Change From Baseline at Week 4 in Proportion of Days Per Week When Experiencing Urgency to Defecate|Change From Baseline at Week 4 in Stool Consistency Scores|Change From Baseline at Week 4 in Stool Frequency|Change From Baseline at Week 4 on the Severity of Bloating|Change From Baseline at Week 4 on the Global Improvement Score.","http://ClinicalTrials.gov/show/NCT00813098","United States"
"82602",82602,"NCT01031498","Palonosetron Versus Ondansetron for the Prevention of Nausea and Vomiting","Completed","No Results Available","Acute Myelogenous Leukemia|Chemotherapy-Induced Nausea and Vomiting","Drug: Ondansetron|Drug: Palonosetron","M.D. Anderson Cancer Center|Eisai Inc.","Both","Adult|Senior","Phase II",150,"Other|Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Supportive Care","2005-0389","December 10, 2009","01/09/2005",2009-09-01,"December 11, 2009","01/12/2009","",2009-09-01,"Number of Emetic Episodes (with no use of rescue medication) During Chemotherapy Administration","http://ClinicalTrials.gov/show/NCT01031498","United States"
"82688",82688,"NCT01187498","Behavioral Treatment of Overactive Bladder in Men","Completed","No Results Available","Overactive Bladder","Behavioral: Behavioral training|Drug: Oxybutynin chloride, extended release","Department of Veterans Affairs","Male","Adult|Senior","Phase III",143,"U.S. Fed","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Open Label|Primary Purpose: Treatment","B3083R","August 20, 2010","01/01/2005",2009-10-01,"August 20, 2010","01/08/2010","MOTIVE",2009-10-01,"24-hour voiding frequency|Urgency severity|Urge incontinence|Nocturia frequency|Patient satisfaction|Patient perception of improvement|American Urological Association (AUA) Symptom Index|Incontinence Impact Questionnaire|Patient global rating of bothersome symptoms|Patient global rating of activity restriction|Patient report of symptom distress|Patient desire for alternate treatment","http://ClinicalTrials.gov/show/NCT01187498","United States"
"82769",82769,"NCT00003199","Combination Chemotherapy and Peripheral Stem Cell Transplantation Followed by Interleukin-2 and Sargramostim in Treating Patients With Inflammatory Stage IIIB or Metastatic Stage IV Breast Cancer","Completed","No Results Available","Breast Cancer","Biological: aldesleukin|Biological: sargramostim|Drug: busulfan|Drug: melphalan|Drug: tamoxifen citrate|Drug: thiotepa|Procedure: bone marrow ablation with stem cell support|Procedure: peripheral blood stem cell transplantation|Radiation: radiation therapy","Fred Hutchinson Cancer Research Center|National Cancer Institute (NCI)","Both","Adult","Phase II",70,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","1229.00|FHCRC-1229.00|PSOC-1605|NCI-G98-1399|CDR0000066035|IR-4559","November 1, 1999","01/11/1997",NA,"October 1, 2010","01/10/2010","",2009-12-01,"","http://ClinicalTrials.gov/show/NCT00003199","United States"
"82831",82831,"NCT00080899","Fenretinide in Treating Patients With Biochemically Recurrent Hormone-Na??ve Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: fenretinide","California Cancer Consortium|National Cancer Institute (NCI)","Male","Child|Adult|Senior","Phase II",37,"Other|NIH","Interventional","Masking: Open Label|Primary Purpose: Treatment","CDR0000357312|CCC-PHII-47|NCI-6168","April 7, 2004","01/06/2004",NA,"October 11, 2010","01/10/2010","",2009-01-01,"Prostate-specific antigen response|Time to clinical progression|Toxicity","http://ClinicalTrials.gov/show/NCT00080899","United States"
"82859",82859,"NCT00113399","Combination Chemotherapy With or Without Radiation Therapy in Treating Patients With Recurrent Head and Neck Cancer That Cannot Be Removed By Surgery","Completed","No Results Available","Head and Neck Cancer","Biological: filgrastim|Drug: cisplatin|Drug: docetaxel|Drug: fluorouracil|Drug: paclitaxel|Radiation: radiation therapy","Radiation Therapy Oncology Group|National Cancer Institute (NCI)","Both","Adult|Senior","Phase III",240,"Other|NIH","Interventional","Allocation: Randomized|Control: Active Control|Primary Purpose: Treatment","CDR0000429480|RTOG-0421|ECOG-R0421","June 7, 2005","01/04/2005",NA,"February 24, 2009","01/02/2009","",2009-02-01,"Survival|Progression-free survival|Grade 5 toxicity rate|Quality of life as assessed by the immediate (acute) side effects of treatment at 3 months|Quality of life as assessed by the late side effects of treatment at 6, 12, 24, and 36 months|Quality-adjusted survival","http://ClinicalTrials.gov/show/NCT00113399","United States"
"82915",82915,"NCT00216099","Pemetrexed as Second-Line Therapy in Treating Patients With Hormone Refractory Prostate Cancer","Completed","No Results Available","Prostate Cancer","Drug: Pemetrexed|Dietary Supplement: Folic Acid|Dietary Supplement: Vitamin B12","Hoosier Oncology Group|Eli Lilly and Company|Walther Cancer Institute","Male","Adult|Senior","Phase II",43,"Other|Industry","Interventional","Allocation: Non-Randomized|Control: Uncontrolled|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Open Label|Primary Purpose: Prevention","HOG GU03-67","September 12, 2005","01/02/2005",2009-03-01,"April 29, 2009","01/04/2009","",2009-03-01,"?? To determine the rates of best overall PSA response (??­ 50% decline in PSA) at any time during the study with single agent pemetrexed in subjects with HRPC whose disease has progressed following one prior taxane based chemotherapy regimen for HRPC??|To determine time to disease progression, overall survival and duration of response (PSA criteria)|To determine OBJECTIVE response per RECIST|To determine the rate of clinical benefit (decreased pain, improved performance status)|To determine the safety and tolerability of pemetrexed in subjects with HRPC whose disease has progressed following one prior taxane-based chemotherapy regimen for HRPC|To explore whether polymorphisms of enzymes involved in pemetrexed metabolism impact its toxicity or efficacy profile","http://ClinicalTrials.gov/show/NCT00216099","United States"
"82916",82916,"NCT00221299","Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use","Completed","No Results Available","Glucocorticoid Induced Osteoporosis","Drug: Risedronate|Drug: Parathyroid Hormone","University of California, Davis|University of California, San Francisco","Both","Adult|Senior","Phase IV",60,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Efficacy Study|Intervention Model: Crossover Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","200513216|RA-015865","September 14, 2005","01/09/2005",2009-05-01,"May 22, 2009","01/05/2009","",2009-03-01,"Bone Mineral Density (BMD): Examine the pattern and effect of BMD changes at hip and spine measured by DXA every 6 months.|Bone Turnover Markers : Evaluate the levels of bone biochemical markers serum total calcium and urinary excretion of calcium.|Incident Vertebral and non-Vertebral Fractures: Evaluate using Instant Vertebral Assessment (IVA) obtained at baseline and annually thereafter.","http://ClinicalTrials.gov/show/NCT00221299","United States"
"83018",83018,"NCT00388999","Intravenous rhMBL in Patients With Multiple Myeloma Receiving Chemotherapy Followed by Stem Cell Transplant","Completed","No Results Available","Multiple Myeloma","Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)|Drug: Intravenous Recombinant Human Mannose-Binding Lectin (rhMBL)","Enzon Pharmaceuticals, Inc.","Both","Adult|Senior","Phase I|Phase II",50,"Industry","Interventional","Allocation: Randomized|Control: Dose Comparison|Endpoint Classification: Safety Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","EZN-2232-01","October 13, 2006","01/09/2006",2009-05-01,"October 19, 2009","01/10/2009","",2009-02-01,"Safety and tolerability of rhMBL|Pharmacokinetic (PK) of rhMBL|Pharmacodynamics (PD) of rhMBL|Immunogenicity of rhMBL, incidence of infectious complications","http://ClinicalTrials.gov/show/NCT00388999","United States"
"83075",83075,"NCT00452699","A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 Mcg BID In Symptomatic Subjects With Asthma","Completed","Has Results","Asthma","Drug: Fluticasone Propionate/salmeterol xinofoate 250/50 mcg BID|Drug: Fluticasone propionate 250 mcg BID","GlaxoSmithKline","Both","Child|Adult|Senior","Phase IV",621,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ADA109055|Fluticasone Propionate/salmete","March 26, 2007","01/05/2007",2009-05-01,"March 4, 2010","01/03/2010","",2009-05-01,"Mean Change From Baseline in Pre-dose FEV1 Over Weeks 1-52|Mean Change From Baseline in AM PEF Over Weeks 1-52|Mean Change From Baseline in the Percentage of Symptom-free Days Over Weeks 1-52|Rate of Asthma Attacks Per Participant Per Year","http://ClinicalTrials.gov/show/NCT00452699","United States, &nbsp; Argentina, &nbsp; Brazil, &nbsp; Canada, &nbsp; Philippines"
"83170",83170,"NCT00615199","A Study to Investigate the Safety and Efficacy of CP-690,550 in Patients With Moderate to Severe Crohn's Disease","Completed","No Results Available","Crohn's Disease","Drug: CP-690,550|Drug: CP-690,550|Drug: CP-690,550","Pfizer","Both","Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","A3921043","January 14, 2008","01/12/2007",2009-10-01,"November 23, 2009","01/11/2009","",2009-10-01,"Clinical response defined by a decrease in the Crohn's disease activity index (CDAI) score of at least 70 points from baseline|Percentage of subjects achieving clinical remission defined as a reduction of CDAI score below 150|Clinical response defined by a decrease in the CDAI score of at least 100 points from baseline|Clinical response defined by a decrease in the CDAI score of at least 70 points from baseline","http://ClinicalTrials.gov/show/NCT00615199","United States, &nbsp; Belgium, &nbsp; Czech Republic, &nbsp; France, &nbsp; Hungary, &nbsp; Italy, &nbsp; Netherlands, &nbsp; Poland, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; United Kingdom"
"83213",83213,"NCT00689299","Phase 2 Study in Adults Sensitized to Cat","Completed","No Results Available","Allergy to Cat Hair","Biological: SLIT","Antigen Laboratories, Inc.","Both","Adult","Phase II",167,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ALI002-08","May 30, 2008","01/10/2008",2009-06-01,"October 14, 2009","01/10/2009","",2009-05-01,"Average of Total Symptom Scores","http://ClinicalTrials.gov/show/NCT00689299","United States"
"83218",83218,"NCT00697099","Evaluation of AVE5026 as Compared to Enoxaparin for the Prevention of Thromboembolism in Patients Undergoing Total Hip Replacement Surgery","Completed","No Results Available","Venous Thromboembolism","Drug: Semuloparin sodium (AVE5026)|Drug: Enoxaparin|Drug: Placebo","Sanofi-Aventis","Both","Adult|Senior","Phase III",2326,"Industry","Interventional","Allocation: Randomized|Control: Active Control|Endpoint Classification: Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Prevention","EFC10342|2007-007944-80","June 12, 2008","01/06/2008",2009-06-01,"December 20, 2010","01/12/2010","SAVE-HIP1",2009-05-01,"Occurence of the composite endpoint of any VTE confirmed by a blinded Central Independent Adjudication Committee (CIAC) and deaths from any cause|Occurence of the composite endpoint of any proximal Deep Vein Thrombosis (DVT), symptomatic distal DVT, nonfatal Pulmonary Embolism (PE), and all cause deaths|Number of patients with major bleedings and clinically relevant non-major bleedings as confirmed by the CIAC","http://ClinicalTrials.gov/show/NCT00697099","United States, &nbsp; Argentina, &nbsp; Australia, &nbsp; Belarus, &nbsp; Canada, &nbsp; Chile, &nbsp; Colombia, &nbsp; Czech Republic, &nbsp; Denmark, &nbsp; Estonia, &nbsp; Finland, &nbsp; Germany, &nbsp; Greece, &nbsp; India, &nbsp; Italy, &nbsp; Mexico, &nbsp; Norway, &nbsp; Peru, &nbsp; Philippines, &nbsp; Poland, &nbsp; Romania, &nbsp; Russian Federation, &nbsp; Slovakia, &nbsp; South Africa, &nbsp; Spain, &nbsp; Sweden, &nbsp; Taiwan, &nbsp; Thailand, &nbsp; Turkey, &nbsp; Ukraine"
"83231",83231,"NCT00720499","Efficacy and Safety of 4 Weeks of Treatment With Orally Inhaled BI1744/Tiotropium Bromide in Patients With Chronic Obstructive Pulmonary Disease (COPD)","Completed","No Results Available","Pulmonary Disease, Chronic Obstructive","Drug: BI1744/Tiotropium bromide","Boehringer Ingelheim Pharmaceuticals","Both","Adult|Senior","Phase II",141,"Industry","Interventional","Endpoint Classification: Safety/Efficacy Study|Intervention Model: Crossover Assignment|Primary Purpose: Treatment","1237.9|EudtaCT No: 2008-000562-23","July 21, 2008","01/07/2008",NA,"March 5, 2009","01/03/2009","",2009-02-01,"The primary efficacy variable will be forced expiratory volume in one second (FEV1). The primary endpoint is the trough FEV1 response [L] after four weeks of treatment.|FEV1 and FVC responses at different timepoints Weekly mean predose morning and evening PEF Weekly mean number of occations of rescue therapy used per day Patient's Global Rating scale Adverse events Laboratory and Vital signs","http://ClinicalTrials.gov/show/NCT00720499","United States, &nbsp; Belgium, &nbsp; Canada, &nbsp; Germany"
"83289",83289,"NCT00811499","Treatment With ARRY-371797 in Patients With Active Ankylosing Spondylitis","Completed","No Results Available","Ankylosing Spondylitis","Drug: ARRY-371797|Drug: Placebo","Array BioPharma","Both","Adult|Senior","Phase II",25,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","ARRAY-797-201","December 17, 2008","01/12/2008",2009-09-01,"December 8, 2009","01/12/2009","",2009-09-01,"Efficacy of ARRY-371797 as measured by ASAS 20 (Assessments in Ankylosing Spondylitis 20% Working Group response criterion)|Safety of ARRY-371797 as measured by adverse events, findings on physical examinations, laboratory abnormalities, change from baseline in vital sign measurements, and change from baseline in 12-lead ECG parameters|Efficacy as measured by ASAS 20, ASAS 40, ASAS 5/6, BASDAI, BASFI, BASMI, EASMI, SPARCC Enthesitis Index, Nocturnal Back Pain, Total Back Pain, Patient's Global Assessment of Disease Activity, SF-36 Health Questionnaire V2 Acute, and CRP|Pharmacokinetics as measured by plasma concentrations of ARRY-371797 and a metabolite|Pharmacodynamics as measured by circulating levels of exploratory biomarkers of disease activity, and sacroiliac (SI) and spinal SPARCC MRI scores","http://ClinicalTrials.gov/show/NCT00811499","United States, &nbsp; Canada"
"83304",83304,"NCT00827099","UCB Transplant, Fludarabine, Melphalan, and ATG in Treating Patients With Hematologic Cancer","Completed","No Results Available","Myeloproliferative Disorders|Leukemia|Lymphoma|Multiple Myeloma and Plasma Cell Neoplasm|Myelodysplastic Syndromes","Biological: anti-thymocyte globulin|Drug: fludarabine phosphate|Drug: melphalan|Drug: mycophenolate mofetil|Drug: tacrolimus|Procedure: nonmyeloablative allogeneic hematopoietic stem cell transplantation|Procedure: umbilical cord blood transplantation","Northside Hospital, Inc.","Both","Adult","Phase II",5,"Other","Interventional","Endpoint Classification: Safety Study|Masking: Open Label|Primary Purpose: Treatment","CDR0000632453|BMTGG-NSH-801","January 21, 2009","01/06/2006",2009-11-01,"March 10, 2010","01/03/2010","",2009-11-01,"Incidence of transplant-related mortality|Incidence of engraftment|Degree of donor-host chimerism|Incidence of acute and chronic graft-vs-host disease|Incidence of relapse|Survival","http://ClinicalTrials.gov/show/NCT00827099","United States"
"83306",83306,"NCT00845299","Study of the Effects of Artificial Tears on the Response to the Latanoprost Punctal Plug Delivery System in Subjects With Ocular Hypertension or Open-Angle Glaucoma","Completed","No Results Available","Glaucoma|Ocular Hypertension","Drug: Latanoprost punctal plug|Drug: artificial tears preserved with Benzalkonium Chloride","QLT Plug Delivery, Inc.","Both","Adult|Senior","Phase II",40,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Open Label|Primary Purpose: Treatment","PPL GLAU 04","February 16, 2009","01/01/2009",2009-12-01,"February 2, 2010","01/02/2010","",2009-12-01,"IOP change from baseline","http://ClinicalTrials.gov/show/NCT00845299","United States"
"83309",83309,"NCT00847899","Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance","Completed","No Results Available","Hypertension|Impaired Glucose Tolerance","Drug: AR9281|Drug: AR9281|Drug: Placebo|Drug: Placebo","Arete Therapeutics","Both","Adult|Senior","Phase II",150,"Industry","Interventional","Allocation: Randomized|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","AR9281-CLN-003","February 17, 2009","01/01/2009",2009-11-01,"November 18, 2009","01/11/2009","",2009-10-01,"Systolic and Diastolic blood pressure|Glucose dynamics and insulin sensitivity","http://ClinicalTrials.gov/show/NCT00847899","United States"
"83330",83330,"NCT00877799","Study to Evaluate Analgesic Effect of Intravenous Administration of Kappa Agonist CR845 After Hysterectomy Surgery","Completed","No Results Available","Acute Pain|Post-operative Pain","Drug: CR845","Cara Therapeutics, Inc.","Female","Adult","Phase II",114,"Industry","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Parallel Assignment|Masking: Double Blind (Subject, Investigator)|Primary Purpose: Treatment","CR845-CLIN2001","April 6, 2009","01/03/2009",2010-01-01,"April 16, 2010","01/04/2010","",2009-12-01,"Analgesic efficacy measured by patient's self reported pain level at rest after surgery (after single dose administration).|Time to onset of analgesic efficacy|Time specific and total level of pain relief|Duration of analgesia|Time specific pain intensity difference from baseline and total level of pain relief|Time and requirement for rescue medication including survival curve of patients requesting rescue medication|Patient satisfaction with study medication with the patient Global evaluation scale|Vital signs, clinical laboratory parameters, ECG|Incidence of adverse events (AEs)|Sedation as measured by Ramsay sedation scale|Anti-inflammatory effects (measured by quantification of serum TNF alpha and serum IL-6","http://ClinicalTrials.gov/show/NCT00877799","United States"
"83542",83542,"NCT01210599","A Pilot Trial of IV Pamidronate for Low Back Pain","Completed","No Results Available","Chronic Low Back Pain","Drug: Pamidronate","Pappagallo, Marco, M.D.","Both","Adult|Senior","Phase I|Phase II",44,"Other","Interventional","Allocation: Randomized|Control: Placebo Control|Endpoint Classification: Safety/Efficacy Study|Intervention Model: Single Group Assignment|Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)|Primary Purpose: Treatment","06-0782","September 27, 2010","01/04/2004",2009-10-01,"October 12, 2010","01/09/2010","",2009-10-01,"","http://ClinicalTrials.gov/show/NCT01210599","United States"
